Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ebfd716a6d868cec0fdcf2af2480107 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-116 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1228 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19 |
filingDate |
2007-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2015-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e499c67dddd4f99810619cc3054a7ac7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bc44b5def49627b938c15f91b3d7dbc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fcac2c25bd73dc2670e215386b32520 |
publicationDate |
2015-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-102731651-B |
titleOfInvention |
Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof |
abstract |
Disclosed is a human monoclonal antibody, wherein said antibody comprises: a heavy chain CDR1 region comprising amino acid sequence SEQ ID NO: 296; a heavy chain CDR2 region comprising amino acid sequence SEQ ID NO: 297; a heavy chain CDR3 region comprising amino acid sequence SEQ ID NO: 298; a light chain CDR1 region comprising amino acid sequence SEQ ID NO: 299; a light chain CDR2 region comprising amino acid sequence SEQ ID NO: 300; a light chain CDR3 region comprising amino acid sequence SEQ ID NO: 301; characterized in that said antibody has opsonic phagocytic killing activity against at least one strain of each of at least two different Enterococcus species and against at least one strain of Staphylococcus aureus. |
priorityDate |
2006-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |